Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference
Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company specializing in intranasal emergency medical treatments, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The virtual presentation will be delivered by CEO Dan Teleman on September 5, 2025, from 7:00-7:30 AM ET.
The company will also be available for one-on-one meetings with investors during the conference, which can be arranged through H.C. Wainwright representatives.
Nasus Pharma (NYSE:NSRX), azienda farmaceutica in fase clinica specializzata in trattamenti medici d'emergenza per via intranasale, ha annunciato la sua partecipazione al H.C. Wainwright 27th Annual Global Investment Conference. La presentazione virtuale sarà tenuta dall'AD Dan Teleman il 5 settembre 2025, dalle 7:00 alle 7:30 ET.
La società sarà inoltre disponibile per incontri one-to-one con gli investitori durante la conferenza; le richieste possono essere organizzate tramite i rappresentanti di H.C. Wainwright.
Nasus Pharma (NYSE:NSRX), compañía farmacéutica en fase clínica especializada en tratamientos médicos de emergencia por vía intranasal, ha anunciado su participación en la H.C. Wainwright 27th Annual Global Investment Conference. La presentación virtual será ofrecida por el CEO Dan Teleman el 5 de septiembre de 2025, de 7:00 a 7:30 a.m. ET.
La compañía también estará disponible para reuniones individuales con inversores durante la conferencia; pueden coordinarse a través de los representantes de H.C. Wainwright.
Nasus Pharma (NYSE:NSRX)는 비강 투여 응급 의료 처치를 전문으로 하는 임상 단계의 제약사로, H.C. Wainwright 27th Annual Global Investment Conference에 참여한다고 발표했습니다. 가상 발표는 최고경영자(CEO) 댄 텔레맨이 2025년 9월 5일 동부표준시(ET) 오전 7시부터 7시 30분까지 진행합니다.
회사는 또한 회의 기간 동안 투자자와의 일대일 미팅도 진행할 예정이며, 미팅 일정은 H.C. Wainwright 담당자를 통해 조율할 수 있습니다.
Nasus Pharma (NYSE:NSRX), société pharmaceutique en phase clinique spécialisée dans les traitements d'urgence par voie intranasale, a annoncé sa participation à la H.C. Wainwright 27th Annual Global Investment Conference. La présentation virtuelle sera faite par le PDG Dan Teleman le 5 septembre 2025, de 07h00 à 07h30 (heure de l'Est).
La société sera également disponible pour des réunions individuelles avec les investisseurs pendant la conférence; celles-ci peuvent être organisées via les représentants de H.C. Wainwright.
Nasus Pharma (NYSE:NSRX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf intranasale Notfallbehandlungen spezialisiert hat, hat seine Teilnahme an der H.C. Wainwright 27th Annual Global Investment Conference angekündigt. Die virtuelle Präsentation wird vom CEO Dan Teleman am 5. September 2025, 7:00–7:30 Uhr ET gehalten.
Das Unternehmen steht während der Konferenz außerdem für Einzelgespräche mit Investoren zur Verfügung; Termine können über die Vertreter von H.C. Wainwright vereinbart werden.
- None.
- None.
TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced that company management will present at the H.C. Wainwright 27th Annual Global Investment Conference.
- Location: Virtual
- Date: September 5, 2025
- Time: 07:00-07:30 a.m. ET
- Type: Company presentation
- Presenter: Dan Teleman, Chief Executive Officer
- Webcast: Registration Link
Nasus management will be available for one-on-one meetings during the conference. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.
About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products.
Contact
info@nasuspharma.com
Nasus Pharma Ltd. Israel
https://www.nasuspharma.com
Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
FAQ
When is Nasus Pharma (NSRX) presenting at the H.C. Wainwright Conference?
Who will be presenting for Nasus Pharma at the H.C. Wainwright Conference?
How can investors attend Nasus Pharma's presentation at the H.C. Wainwright Conference?
How can investors schedule one-on-one meetings with Nasus Pharma management?
